GLP-1 receptor agonists such as semaglutide and tirzepatide are FDA-regulated for chronic weight management in adults with a BMI of 30 or higher, or 27 with a weight-related condition. In the Technology City of the South, long sedentary days, catered lunches and back-to-back meetings quietly drive weight gain among otherwise high-functioning professionals. Telehealth fits a packed corporate calendar: a licensed Georgia physician reviews your online assessment under Georgia Telehealth Act (O.C.G.A. §33-24-56.4), and compounded medication from an FDA-registered 503B pharmacy ships to your Johns Creek home or office. Monthly cost runs $199–$379 versus about $1,247 for brand-name Ozempic or Wegovy. Medical Director: Dr. Patricia Johnson, MD, Board-Certified Family Medicine.
Residents of Johns Creek, part of the greater Alpharetta, GA metro, near local landmarks such as FCS Innovation Academy, Independence High School Georgia and National Christian Foundation, can begin a physician-reviewed GLP-1 or tirzepatide weight-loss program without ever setting foot in a clinic.
Yes. Georgia Telehealth Act (O.C.G.A. §33-24-56.4) lets a Georgia-licensed physician prescribe weight-management drugs including semaglutide through telehealth, by video or reviewed questionnaire. Oversight comes from the Georgia Composite Medical Board at medicalboard.georgia.gov. No prior in-person visit is required - ideal for Johns Creek professionals who can't block out clinic time.
Yes. A Johns Creek resident can complete an online assessment and, when appropriate, receive a GLP-1 prescription within 24 to 48 hours without setting foot in a clinic. The prescriber must be licensed in Georgia and comply with Georgia Telehealth Act (O.C.G.A. §33-24-56.4).
Under the Georgia Composite Medical Board (medicalboard.georgia.gov), telehealth clinicians serving Johns Creek must hold Georgia licensure, document every encounter and secure informed consent. Any compounded medication must originate from an FDA-registered 503B outsourcing facility - the same standard a corporate health plan would expect.
No - Georgia Telehealth Act (O.C.G.A. §33-24-56.4) permits prescribing without a prior in-person relationship for patients throughout Johns Creek and Georgia. A video consult or physician-reviewed questionnaire satisfies the standard of care under Georgia Composite Medical Board rules, so professionals can start from their desk.
Yes. Every licensed provider serving Johns Creek operates under HIPAA: encrypted data, business associate agreements with pharmacy partners, and tight controls on access to your records. Your health information stays as protected as any enterprise system you trust at work.
Brand-name GLP-1 drugs run about $1,247/month at Johns Creek pharmacies. Through telehealth, compounded semaglutide produced under 503B standards typically costs $199–$379/month including the prescription - a rounding error for many professionals, but with far more convenience than a clinic.
It varies by plan. Many employer plans exclude weight-loss drugs or require prior authorization and a qualifying BMI, and Medicare excludes Wegovy for weight loss. Plenty of Johns Creek professionals simply pay cash for compounded semaglutide at $199–$379/month rather than fight the approval process.
Alpharetta professionals who hit a plan exclusion - or who value speed and privacy - increasingly pay cash for compounded semaglutide through telehealth. At $199–$379/month against roughly $1,247/month retail for branded versions, it is both cheaper and faster than prior authorization.
In-person clinics serving Johns Creek typically charge 150 to 300 dollars per visit plus medication. A telehealth program at $199–$379/month removes travel and per-visit cost, with compounded GLP-1 medication shipped from a 503B pharmacy to wherever you work.
Semaglutide is a synthetic version of GLP-1, a hormone the gut secretes after meals. By boosting glucose-triggered insulin, suppressing glucagon, slowing gastric emptying and dampening appetite in the brain, it produces durable weight loss - a counterweight to the sitting, snacking and stress that define a desk-bound career.
Both are GLP-1 receptor agonists, but tirzepatide (Mounjaro, Zepbound) also activates the GIP receptor, a second incretin pathway. That dual action drove higher average loss in trials - roughly 22.5 percent in SURMOUNT-1 versus 14.9 percent for semaglutide in STEP-1. Telehealth clinicians in GA can prescribe either to Johns Creek patients.
Yes for the brands: Wegovy (semaglutide 2.4 mg weekly) was approved in June 2021 for a BMI of 30 or higher, or 27 with a related condition, and Ozempic is approved for type 2 diabetes. Compounded semaglutide, while not an approved product, is made by 503B facilities under Section 503B of the FD&C Act.
Published in NEJM in 2021, STEP-1 followed adults on semaglutide 2.4 mg weekly and recorded an average 14.9 percent body-weight reduction over 68 weeks against 2.4 percent for placebo. The follow-up STEP-4 trial showed weight returns after stopping - so Johns Creek clinicians plan for sustained, not short-term, treatment.
Per FDA labeling, candidates are adults with a BMI of 30 or higher, or 27 or higher alongside a condition like hypertension, type 2 diabetes or dyslipidemia. Providers serving Johns Creek apply these same thresholds, verified through your online assessment and reported history.
For Johns Creek patients, most providers set the bar at a BMI of 27 or higher when paired with a related condition such as prediabetes or high blood pressure, or 30 or higher by itself. Initial screening accepts your reported numbers; the physician may verify them before issuing a prescription.
Reported by more than one in ten trial participants: nausea, vomiting, diarrhea, constipation and abdominal discomfort, peaking during dose increases. Uncommon but serious risks include pancreatitis and gallbladder disease. The prescriber screens contraindications, including any personal or family history of medullary thyroid carcinoma, before you begin.
A standard panel - comprehensive metabolic panel, CBC, HbA1c, lipids and TSH - is typical before starting. Recent results from your primary care doctor are often accepted, and Johns Creek professionals can knock out any gaps at a nearby Quest or LabCorp on the way to the office.
Two-year extension data from SUSTAIN and STEP indicate a consistent safety profile with continuous use. In the 2023 SELECT trial, semaglutide cut major adverse cardiovascular events by 20 percent in adults with overweight or obesity and existing heart disease - relevant to sedentary professionals carrying cardiovascular risk.
Yes. As Ozempic, semaglutide is FDA-approved for glycemic control in type 2 diabetes and routinely prescribed by telehealth clinicians serving Johns Creek. When obesity and diabetes coexist it treats both. Disclose every current medication in your assessment so the physician can check for interactions.
It runs in four steps: complete a 10 to 15 minute assessment online; a Georgia-licensed physician reviews it within 24 hours; an approved prescription goes to a 503B pharmacy; and medication ships to your Johns Creek address. No in-person visit is required under Georgia Telehealth Act (O.C.G.A. §33-24-56.4) - the whole thing happens between meetings.
Most Johns Creek patients have a prescription decision within 24 to 48 hours of completing the assessment, followed by overnight temperature-controlled delivery. Shipments to Johns Creek ZIP codes 30004, 30005, 30009, 30022 generally land within one to two business days of approval.
The consult covers your assessment answers, medical history and current medications, BMI and any comorbidities, and the dosing plan, finishing with a prescription where appropriate. Dr. Patricia Johnson, MD, Board-Certified Family Medicine, supervises clinical review for Johns Creek patients - the diligence of an in-person visit without leaving your desk.
It is a once-weekly subcutaneous injection delivered with a pre-filled pen. Dosing opens at 0.25 mg weekly for four weeks and climbs over 16 to 20 weeks to a 2.4 mg maintenance level. Guidance ships with your first order, and most Johns Creek patients administer it in seconds at home.
Refrigerate unopened pens at 36 to 46 F. Once in use, a pen tolerates room temperature up to 77 F for 28 days. Avoid freezing and direct sunlight, and bring deliveries indoors promptly rather than leaving them on a warm Georgia porch.
Georgia reports an uninsured rate of 12.9%, and many employer plans simply exclude weight-loss medications. For Johns Creek professionals in that gap, a cash-pay telehealth program at $199–$379/month is a clean alternative to clinic-based treatment.
The deciding factors in Johns Creek are time and discretion: no day off, no GA-400 traffic to a clinic, no waiting room, predictable $199–$379/month cost, and no prior-auth delay. For professionals who manage their lives by calendar, weight-loss care that never books an appointment is the obvious choice.
Glucagon-like peptide-1 is an incretin hormone your intestines release in response to food. A GLP-1 receptor agonist is a lab-made molecule that mimics and amplifies that hormone, used to manage type 2 diabetes and, at higher doses, body weight. For Johns Creek residents, telehealth has made this class far easier to access since 2022.
Ozempic and Wegovy are both Novo Nordisk brand names for semaglutide; Ozempic (0.5 to 2 mg weekly) is the diabetes formulation and Wegovy (2.4 mg weekly) the weight-management one. Compounded semaglutide delivers the identical active ingredient at lower cost through licensed GA telehealth providers.
FDA-registered 503B outsourcing facilities legally compound semaglutide under Section 503B of the FD&C Act, even though the compounded form itself is not an FDA-approved product. The agency issued shortage-related compounding guidance across 2024 and 2025. GA-licensed clinicians may prescribe it to Johns Creek patients when clinically appropriate.
Titration follows five steps - 0.25, 0.5, 1.0, 1.7 and 2.4 mg weekly - holding roughly four weeks at each before advancing. Johns Creek patients who feel pronounced GI effects can extend any step, keeping side effects from interfering with a demanding workweek.
Average loss in STEP-1 was 14.9 percent of body weight over 68 weeks on semaglutide 2.4 mg weekly. Among Johns Creek patients who complete the full titration, real-world outcomes typically span 8 to 20 percent, shaped by consistency, diet and starting weight.
Clinical content here is reviewed by Dr. Patricia Johnson, MD, Board-Certified Family Medicine, who is licensed in Georgia. Prescriptions are issued only after a Georgia-licensed physician reviews your assessment, and the program operates under Georgia Telehealth Act (O.C.G.A. §33-24-56.4) and Georgia Composite Medical Board standards - corporate-grade accountability, delivered online to Johns Creek.
GLP-1 Telehealth Alpharetta links Johns Creek residents with licensed physicians for FDA-regulated GLP-1 therapy, designed for professionals whose schedules leave no room for clinics. The team focuses on metabolic and weight-management telehealth. Medical Director: Dr. Patricia Johnson, MD, Board-Certified Family Medicine. We serve patients across Johns Creek and the north metro Atlanta corridor.
Medical Director: Dr. Patricia Johnson, MD, Board-Certified Family Medicine. Licensed in Georgia. All prescriptions issued under Georgia Telehealth Act (O.C.G.A. §33-24-56.4) and supervised by Georgia Composite Medical Board.